<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d178" origId="Gefitinib"><sentence id="DrugDDI.d178.s0" origId="s0" text="Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations."><entity id="DrugDDI.d178.s0.e0" origId="s0.p4" charOffset="32-38" type="drug" text="CYP3A4"/><entity id="DrugDDI.d178.s0.e1" origId="s0.p7" charOffset="75-84" type="drug" text="gefitinib"/><pair id="DrugDDI.d178.s0.p0" e1="DrugDDI.d178.s0.e0" e2="DrugDDI.d178.s0.e1" interaction="?"/></sentence><sentence id="DrugDDI.d178.s1" origId="s1" text="In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections)."><entity id="DrugDDI.d178.s1.e0" origId="s1.p13" charOffset="31-37" type="drug" text="CYP3A4"/><entity id="DrugDDI.d178.s1.e1" origId="s1.p14" charOffset="54-64" type="drug" text="rifampicin"/><entity id="DrugDDI.d178.s1.e2" origId="s1.p16" charOffset="68-77" type="drug" text="phenytoin"/><pair id="DrugDDI.d178.s1.p0" e1="DrugDDI.d178.s1.e0" e2="DrugDDI.d178.s1.e1" interaction="?"/><pair id="DrugDDI.d178.s1.p1" e1="DrugDDI.d178.s1.e0" e2="DrugDDI.d178.s1.e2" interaction="?"/><pair id="DrugDDI.d178.s1.p2" e1="DrugDDI.d178.s1.e1" e2="DrugDDI.d178.s1.e2" interaction="?"/></sentence><sentence id="DrugDDI.d178.s2" origId="s2" text="International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy."><entity id="DrugDDI.d178.s2.e0" origId="s2.p52" charOffset="114-122" type="drug" text="warfarin"/><entity id="DrugDDI.d178.s2.e1" origId="s2.p54" charOffset="132-138" type="drug" text="IRESSA"/><pair id="DrugDDI.d178.s2.p0" e1="DrugDDI.d178.s2.e0" e2="DrugDDI.d178.s2.e1" interaction="?"/></sentence><sentence id="DrugDDI.d178.s3" origId="s3" text="Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR."><entity id="DrugDDI.d178.s3.e0" origId="s3.p57" charOffset="16-24" type="drug" text="warfarin"/></sentence><sentence id="DrugDDI.d178.s4" origId="s4" text="Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations."><entity id="DrugDDI.d178.s4.e0" origId="s4.p70" charOffset="41-47" type="drug" text="CYP3A4"/><entity id="DrugDDI.d178.s4.e1" origId="s4.p73" charOffset="62-74" type="drug" text="ketoconazole"/><entity id="DrugDDI.d178.s4.e2" origId="s4.p75" charOffset="79-91" type="drug" text="itraconazole"/><entity id="DrugDDI.d178.s4.e3" origId="s4.p78" charOffset="102-111" type="drug" text="gefitinib"/><entity id="DrugDDI.d178.s4.e4" origId="s4.p80" charOffset="136-145" type="drug" text="gefitinib"/><pair id="DrugDDI.d178.s4.p0" e1="DrugDDI.d178.s4.e0" e2="DrugDDI.d178.s4.e1" interaction="?"/><pair id="DrugDDI.d178.s4.p1" e1="DrugDDI.d178.s4.e0" e2="DrugDDI.d178.s4.e2" interaction="?"/><pair id="DrugDDI.d178.s4.p2" e1="DrugDDI.d178.s4.e0" e2="DrugDDI.d178.s4.e3" interaction="?"/><pair id="DrugDDI.d178.s4.p3" e1="DrugDDI.d178.s4.e0" e2="DrugDDI.d178.s4.e4" interaction="?"/><pair id="DrugDDI.d178.s4.p4" e1="DrugDDI.d178.s4.e1" e2="DrugDDI.d178.s4.e2" interaction="?"/><pair id="DrugDDI.d178.s4.p5" e1="DrugDDI.d178.s4.e1" e2="DrugDDI.d178.s4.e3" interaction="?"/><pair id="DrugDDI.d178.s4.p6" e1="DrugDDI.d178.s4.e1" e2="DrugDDI.d178.s4.e4" interaction="?"/><pair id="DrugDDI.d178.s4.p7" e1="DrugDDI.d178.s4.e2" e2="DrugDDI.d178.s4.e3" interaction="?"/><pair id="DrugDDI.d178.s4.p8" e1="DrugDDI.d178.s4.e2" e2="DrugDDI.d178.s4.e4" interaction="?"/><pair id="DrugDDI.d178.s4.p9" e1="DrugDDI.d178.s4.e3" e2="DrugDDI.d178.s4.e4" interaction="?"/></sentence><sentence id="DrugDDI.d178.s5" origId="s5" text="This increase may be clinically relevant as adverse experiences are related to dose and exposure;"/><sentence id="DrugDDI.d178.s6" origId="s6" text="therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA."><entity id="DrugDDI.d178.s6.e0" origId="s6.p98" charOffset="53-59" type="drug" text="CYP3A4"/><entity id="DrugDDI.d178.s6.e1" origId="s6.p99" charOffset="76-82" type="drug" text="IRESSA"/><pair id="DrugDDI.d178.s6.p0" e1="DrugDDI.d178.s6.e0" e2="DrugDDI.d178.s6.e1" interaction="?"/></sentence><sentence id="DrugDDI.d178.s7" origId="s7" text="Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy."><entity id="DrugDDI.d178.s7.e0" origId="s7.p100" charOffset="0-5" type="drug" text="Drugs"/><entity id="DrugDDI.d178.s7.e1" origId="s7.p106" charOffset="64-97" type="drug" text="histamine h2-receptor antagonists"/><entity id="DrugDDI.d178.s7.e2" origId="s7.p107" charOffset="106-116" type="drug" text="ranitidine"/><entity id="DrugDDI.d178.s7.e3" origId="s7.p109" charOffset="120-130" type="drug" text="cimetidine"/><entity id="DrugDDI.d178.s7.e4" origId="s7.p114" charOffset="168-174" type="drug" text="IRESSA"/><pair id="DrugDDI.d178.s7.p0" e1="DrugDDI.d178.s7.e0" e2="DrugDDI.d178.s7.e1" interaction="?"/><pair id="DrugDDI.d178.s7.p1" e1="DrugDDI.d178.s7.e0" e2="DrugDDI.d178.s7.e2" interaction="?"/><pair id="DrugDDI.d178.s7.p2" e1="DrugDDI.d178.s7.e0" e2="DrugDDI.d178.s7.e3" interaction="?"/><pair id="DrugDDI.d178.s7.p3" e1="DrugDDI.d178.s7.e0" e2="DrugDDI.d178.s7.e4" interaction="?"/><pair id="DrugDDI.d178.s7.p4" e1="DrugDDI.d178.s7.e1" e2="DrugDDI.d178.s7.e2" interaction="?"/><pair id="DrugDDI.d178.s7.p5" e1="DrugDDI.d178.s7.e1" e2="DrugDDI.d178.s7.e3" interaction="?"/><pair id="DrugDDI.d178.s7.p6" e1="DrugDDI.d178.s7.e1" e2="DrugDDI.d178.s7.e4" interaction="?"/><pair id="DrugDDI.d178.s7.p7" e1="DrugDDI.d178.s7.e2" e2="DrugDDI.d178.s7.e3" interaction="?"/><pair id="DrugDDI.d178.s7.p8" e1="DrugDDI.d178.s7.e2" e2="DrugDDI.d178.s7.e4" interaction="?"/><pair id="DrugDDI.d178.s7.p9" e1="DrugDDI.d178.s7.e3" e2="DrugDDI.d178.s7.e4" interaction="?"/></sentence><sentence id="DrugDDI.d178.s8" origId="s8" text="Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine."><entity id="DrugDDI.d178.s8.e0" origId="s8.p121" charOffset="36-42" type="drug" text="IRESSA"/><entity id="DrugDDI.d178.s8.e1" origId="s8.p123" charOffset="47-58" type="drug" text="vinorelbine"/><entity id="DrugDDI.d178.s8.e2" origId="s8.p129" charOffset="103-109" type="drug" text="IRESSA"/><entity id="DrugDDI.d178.s8.e3" origId="s8.p133" charOffset="151-162" type="drug" text="vinorelbine"/><pair id="DrugDDI.d178.s8.p0" e1="DrugDDI.d178.s8.e0" e2="DrugDDI.d178.s8.e1" interaction="?"/><pair id="DrugDDI.d178.s8.p1" e1="DrugDDI.d178.s8.e0" e2="DrugDDI.d178.s8.e2" interaction="?"/><pair id="DrugDDI.d178.s8.p2" e1="DrugDDI.d178.s8.e0" e2="DrugDDI.d178.s8.e3" interaction="?"/><pair id="DrugDDI.d178.s8.p3" e1="DrugDDI.d178.s8.e1" e2="DrugDDI.d178.s8.e2" interaction="?"/><pair id="DrugDDI.d178.s8.p4" e1="DrugDDI.d178.s8.e1" e2="DrugDDI.d178.s8.e3" interaction="?"/><pair id="DrugDDI.d178.s8.p5" e1="DrugDDI.d178.s8.e2" e2="DrugDDI.d178.s8.e3" interaction="?"/></sentence></document>